We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Significant overall survival benefit with dostarlimab plus chemotherapy in advanced endometrial cancer.
- Authors
Nierengarten, Mary Beth
- Abstract
A recent study presented at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer found that women with advanced or recurrent endometrial cancer who were treated with dostarlimab plus chemotherapy had a 31% lower risk of death compared to those treated with chemotherapy alone. The study also showed that patients with deficient mismatch repair (dMMR)/microsatellite instability (MSI)-high tumors had a 68% lower risk of death with the combination therapy. These findings are significant and offer hope for patients with advanced or recurrent endometrial cancer. The study included 494 patients and found no new safety concerns associated with the treatment.
- Subjects
ENDOMETRIAL cancer; OVERALL survival; CANCER chemotherapy
- Publication
Cancer (0008543X), 2024, Vol 130, Issue 13, p2245
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.35372